Introducing DPP HIV-Syphilis: The First & Only FDA Approved HIV-Syphilis Rapid Test


Introducing DPP® COVID-19 IgM/IgG System in Brazil


Launching the First Rapid Zika IgM Test with FDA 510(k) Clearance


Stay up to date with our latest news.


Chembio Diagnostics Receives ANVISA Approval for DPP SARS-CoV-2 Antigen Test System in Brazil

Nov 13, 2020 HAUPPAUGE, N.Y. (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostic company…

Chembio Diagnostics Submits EUA Application for DPP SARS-CoV-2 Antigen Test System

Oct 15, 2020: Rapid Test Provides Results in Only 20 Minutes HAUPPAUGE, N.Y., Oct. 15, 2020 (GLOBE…

Chembio Diagnostics Receives FDA Approval for DPP HIV-Syphilis System

Oct 2, 2020: First Rapid Test Approved in U.S. to Aid in Diagnosis of Both…
About Us

We enable longer and healthier living through detection and monitoring of infectious diseases at the point of care.

Our mission is to be a leader in the development, manufacturing and commercialization of diagnostic solutions. We are dedicated to delivering exceptional point-of-care products that are easy to use, fast and accurate.

Our Core Values: “RAPID”






Learn More
Investor Relations

Chembio is a leading point of care diagnostics company focused on detecting and diagnosing infectious diseases.

Our patented DPP® technology platform uses a small drop of blood from the fingertip and provides high-quality, cost-effective results in 15-20 minutes. Our products are sold globally, directly and through distributors, to hospitals, clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers.

Learn More
Chembio Testing

We are looking for talented, dedicated people wishing to contribute to our common vision of enhancing the health and well being of people worldwide.